A Randomised, Double-blind, Placebo-controlled, Phase Ib Study Evaluating the Safety and Tolerability of IRL790 in Patients With Parkinson's Disease (PD) Experiencing Levodopa (L-Dopa) Induced Dyskinesia (LID)
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Mesdopetam (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Integrative Research Laboratories
- 09 Oct 2018 Results presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders
- 27 Nov 2017 New trial record